Table 3.
Outcome | Siblings, n (%) | All ALL survivors, n (%) | OR for all ALL survivors vs siblings (95% CI) † | P | Nonrelapsed, nonirradiated survivors, n (%) | OR for nonrelapsed, nonirradiated survivors vs siblings (95% CI)† | P |
---|---|---|---|---|---|---|---|
Number in each group | 3083 | 2599 | 426 | ||||
Chronic medical conditions | |||||||
Hearing | 12 (0.4) | 27 (1.0) | 3.0 (1.5-6.8) | <.001 | 4 (0.9) | 2.7 (0.5-7.8) | .17 |
Vision | 21 (0.7) | 30 (1.2) | 1.6 (0.9-3.1) | .19 | 2 (0.5) | 0.5 (0.1-1.6) | .26 |
Endocrine | 56 (1.8) | 114 (4.4) | 3.1 (2.3-4.5) | <.001 | 5 (1.2) | 1.0 (0.2-2.2) | .96 |
Pulmonary | 37 (1.2) | 78 (3.0) | 4.2 (2.8-6.6) | <.001 | 8 (1.9) | 2.7 (1.0-5.1) | .05 |
Cardiac | 21 (0.7) | 82 (3.2) | 6.9 (4.212.9) | <.001 | 6 (1.4) | 3.8 (0.9-10.0) | .06 |
Gastrointestinal | 14 (0.5) | 18 (0.7) | 2.2 (1.0-5.0) | .04 | 1 (0.2) | 1.0 (0.2-5.7) | .96 |
Renal | 5 (0.2) | 21 (0.8) | 4.8 (2.118.9) | <.001 | 2 (0.5) | 4.1 (0.5-37.0) | .29 |
Musculoskeletal | 3 (0.1) | 14 (0.5) | 7.7 (2.821.3) | <.001 | 4 (0.9) | 22.8 (4.0-128.1) | .03 |
Neurologic | 13 (0.4) | 62 (2.4) | 5.3 (3.111.4) | <.001 | 3 (0.7) | 1.6 (0.5-5.4) | .49 |
Grade 3 to 4 | 179 (5.8) | 382 (14.7) | 3.7 (3.0-4.5) | <.001 | 34 (8.0) | 2.0 (1.3-3.0) | .01 |
2 or more in grades 1 to 4 | 433 (14.0) | 667 (25.7) | 2.8 (2.4-3.2) | <.001 | 73 (17.1) | 1.9 (1.4-2.5) | <.001 |
Adverse health status | |||||||
General health | 157 (5.1) | 230 (8.9) | 2.1 (1.6-2.7) | <.001 | 24 (5.6) | 1.2 (0.7-1.9) | .45 |
Mental health | 302 (9.8) | 389 (15.0) | 1.7 (1.4-2.0) | <.001 | 61 (14.3) | 1.6 (1.1-2.1) | .01 |
Activity limitation | 178 (5.8) | 230 (8.9) | 1.8 (1.5-2.3) | <.001 | 28 (6.6) | 1.3 (0.8-2.0) | .25 |
Functional impairment | 79 (2.6) | 227 (8.7) | 4.1 (3.1-5.6) | <.001 | 18 (4.2) | 2.0 (1.0-3.3) | .05 |
CI indicates confidence interval.
* Adjusted for age at interview, sex, and ethnicity.
Adjusted for cumulative anthracycline dose, alkylator score, age at interview, age at diagnosis, sex, and ethnicity.